Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
701-720 of 1,307 trials

Breast Cancer: Fezolinetant for Hot Flashes

We are studying whether fezolinetant can help reduce hot flashes in women with hormone receptor-positive breast cancer receiving hormone therapy. The trial also looks at how this treatment affects quality of life and sleep.

Hot Flashes1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteEndocrinologyOncology

Hidradenitis Suppurativa: Lutikizumab Study

We are evaluating the effectiveness and safety of lutikizumab for treating moderate to severe hidradenitis suppurativa in adults and adolescents. This study compares lutikizumab to a placebo to see how well it works.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Whipple's Procedure: Antibiotic Treatment Comparison

We are studying whether pre-emptive antibiotics can lower the risk of infections after Whipple's surgery compared to standard antibiotic treatment. This trial aims to improve recovery outcomes for patients undergoing this procedure.

Pancreatoduodenectomy with High Risk for Contaminated Bile>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Hyperbaric Oxygen Therapy for Sudden Hearing Loss

We are studying whether adding hyperbaric oxygen treatment to standard care improves hearing in people with sudden sensorineural hearing loss. The trial will also look at quality of life and safety of this treatment approach.

Sudden Hearing Loss3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOtolaryngology

Ulcerative Colitis: CICR-NAM Treatment Study

We are testing a new oral medication for people with mild to moderately active ulcerative colitis. The goal is to see if it helps improve symptoms and overall gut health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterology

Brain Radionecrosis: Bevacizumab vs. Placebo

We are studying whether adding bevacizumab to standard corticosteroid therapy helps improve symptoms and reduce steroid use in patients with brain radionecrosis after radiotherapy. This trial also looks at safety and quality of life.

Brain Metastases and Radionecrosis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesNeurologyOncology

Advanced Melanoma: Relatlimab with Nivolumab Study

We are investigating whether combining Relatlimab with Nivolumab helps people with untreated advanced melanoma live longer and have better outcomes than Nivolumab alone.

Metastatic Melanoma1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Angelman Syndrome: GTX-102 Treatment Study

We are investigating the long-term safety and effectiveness of GTX-102 for individuals with Angelman Syndrome. The study looks at improvements in cognitive function, communication, and motor skills.

Angelman's SyndromeConfirmation phase (III)No PlaceboInvestigational MedicinesNeurology

Cytoreductive Surgery: Albumin and Ringer Lactate Study

We are testing whether a combination of 20% albumin and Ringer Lactate improves recovery after surgery for patients with peritoneal carcinosis. This study compares it to Ringer Lactate alone to see which is more effective.

Peritoneal Carcinomatosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsInternal MedicineOncology

Prolonged Seizures: Staccato Alprazolam Study

We are investigating whether Staccato Alprazolam is safe and effective for quickly stopping prolonged seizures in individuals aged 12 and older. The study compares its effects to a placebo to assess its benefits.

Prolonged Seizure3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Dexamethasone for Advanced Multiple Myeloma

We are studying a free treatment regimen of Dexamethasone for patients with advanced relapsed or refractory multiple myeloma. The goal is to see how well it works in improving response rates and quality of life.

Multiple Myeloma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Mucopolysaccharidosis Type II: DNL310 vs Idursulfase

We are studying a new treatment, DNL310, for children and young adults with Mucopolysaccharidosis Type II to see if it works better than the current treatment, Idursulfase, in improving brain and physical health.

Hunter's Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyNeurology

Systemic Sclerosis Prevention: Clopidogrel Study

We are investigating if Clopidogrel can reduce the risk of developing systemic sclerosis in patients with specific immune conditions and Raynaud phenomenon. The study compares its effects to a placebo over several years.

Raynaud Phenomenon>2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesInternal MedicineRheumatology

Sedation Methods in TAVR Procedures

We are comparing different sedation techniques for patients undergoing Transcatheter Aortic Valve Replacement. The goal is to see if one method reduces breathing problems and confusion after the procedure.

Aortic Stenosis1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyGastroenterologyInternal MedicineOtolaryngologyPsychiatry

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology

Ampullary Adenocarcinoma: mFOLFIRINOX vs. Gemcitabine or Capecitabine

We are studying whether a combination chemotherapy can improve survival rates for patients after surgery for ampullary adenocarcinoma. The trial also looks at quality of life and side effects compared to standard treatments.

Ampullary Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Denosumab for Fibrous Dysplasia and McCune-Albright Syndrome

We are studying whether Denosumab can help reduce pain and improve quality of life for adults with Fibrous Dysplasia and McCune-Albright Syndrome. The trial will also look at its effects on mobility and bone health.

Fibrous Dysplasia/McCune-Albright Syndrome1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Myotonic Dystrophy: Long-Term Study of Mexiletine PR

We are examining the long-term safety and effectiveness of mexiletine PR for treating myotonia in patients with myotonic dystrophy types 1 and 2. This study is for those who have completed a prior related study.

Myotonic Dystrophy1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Myotonic Dystrophy: Mexiletine PR Study

We are investigating whether once daily mexiletine can help reduce muscle stiffness in patients with myotonic dystrophy types 1 and 2. The study will also look at its safety and how it affects daily activities.

Myotonic Dystrophy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology